| Literature DB >> 26443969 |
Yuki Yoshimatsu1, Takuya Kotani2, Youhei Fujiki2, Katsuhiro Oda2, Toshiya Kataoka3, Kazushi Yamairi1, Kenichiro Hata4, Kenichiro Otani1, Takao Kamimori1, Hiroshi Fujiwara1.
Abstract
Cardiomyopathy and rapid progressive interstitial pneumonia (IP) are potentially fatal complications in polymyositis/dermatomyositis. We experienced a dermatomyositis patient with multiple adverse prognostic factors, complicating rapid progressive IP, macrophage activation syndrome (MAS), and cardiomyopathy. IP and MAS improved with strong immunosuppressive therapy, despite which cardiomyopathy developed. Therefore, we applied intravenous high-dose immunoglobulin therapy (IVIg), and cardiac function improved dramatically. This is the first report to present the effectiveness of IVIg for cardiomyopathy in dermatomyositis.Entities:
Keywords: clinical aspects (myositis and related syndromes); drug treatment (myositis and related syndromes); myositis and related syndromes
Mesh:
Substances:
Year: 2015 PMID: 26443969 DOI: 10.1111/1756-185X.12746
Source DB: PubMed Journal: Int J Rheum Dis ISSN: 1756-1841 Impact factor: 2.454